We rank companies based on fund manager, research analyst and news sentiment
XBIO stock icon

Xenetic Biosciences


About: Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.

Employees: 4

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 7 [Q3] → 7 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.03% less ownership

Funds ownership: 1.13% [Q3] → 1.1% (-0.03%) [Q4]

24% less capital invested

Capital invested by funds: $79.4K [Q3] → $60.7K (-$18.7K) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Research analyst outlook

We haven’t received any recent analyst ratings for XBIO.

Financial journalist opinion